News | January 05, 2009

Micro-Bubble Echo Contrast Procedures Rebounded in 2008

January 5, 2009 - Arlington Medical Resources (AMR), a provider of market intelligence for the pharmaceutical and diagnostic imaging industries, reported that the number of micro-bubble echo contrast procedures performed in October 2008 have increased by more than 50 percent, to nearly 18,000 procedures, when compared to May 2008.

Micro-bubble echo contrast procedures began declining sharply in October 2007, from nearly 55,000 procedures in September 2007, as a result of a black box warning issued by the FDA in October 2007.

A revised black box warning issued in May 2008 has contributed to this rebound as well as physicians and sonographers reestablishing protocols for contrast usage in their institutions. A micro-bubble echo contrast agent is administered intravenously and used for contrast enhancement during echocardiographic procedures.

The newly released edition of the U.S. Echocardiography Monthly Monitor also finds that both Lantheus Medical Imaging's Definity and GE Healthcare’s Optison -- the two FDA approved micro-bubble echo contrast agents -- realized increased usage during the same study period.

For more information: www.AMR-data.com

Related Content

Study Finds No Evidence that Gadolinium Causes Neurologic Harm

MR images through, A, C, E, basal ganglia and, B, D, F, posterior fossa at level of dentate nucleus. Images are shown for, A, B, control group patient 4, and the, C, D, first and, E, F, last examinations performed in contrast group patient 13. Regions of interest used in quantification of signal intensity are shown as dashed lines for globus pallidus (green), thalamus (blue), dentate nucleus (yellow), and pons (red).

News | Contrast Media | January 11, 2018
January 11, 2018 — There is no evidence that accumulation in the brain of the element gadolinium speeds cognitive dec
Male Triathletes May Be Putting Their Heart Health at Risk
News | Cardiac Imaging | January 09, 2018
Competitive male triathletes face a higher risk of a potentially harmful heart condition called myocardial fibrosis,...
Videos | Magnetic Resonance Imaging (MRI) | December 19, 2017
Emanuel Kanal, M.D., director of MRI services and professor of radiology and neuroradiology at the University of Pitt
The FDA issued new warnings on MRI gadolinium contrast agents. (GBCAs)

The FDA issued new warnings on MRI gadolinium contrast agents. 

Feature | Magnetic Resonance Imaging (MRI) | December 19, 2017
The U.S.
Brainlab Contrast Clearance Analysis Software Receives FDA 510(k) Clearance
Technology | Contrast Media | December 12, 2017
Brainlab announced U.S. Food and Drug Administration (FDA) clearance of its Contrast Clearance Analysis methodology,...
Sectra Offers Gadolinium Tracking Functionality in DoseTrack Software
Technology | Contrast Media | December 11, 2017
December 11, 2017 — Sectra recently announced the global introduction of gadolinium tracking in its dose monitoring s
Videos | Magnetic Resonance Imaging (MRI) | December 07, 2017
Max Wintermark, M.D., professor of radiology and chief of neuroradiology, Stanford Hospital and Clinics, discussed MR
Guerbet to Participate in French Interventional Radiology Conference
News | Contrast Media | October 10, 2017
Guerbet announced it will be taking part in the 65th edition of the Journées Francophones de Radiologie (JFR) that will...
Trends in contrast media used in magnetic resonance imaging and computed tomography

Image courtesy of Bayer

Feature | Contrast Media | October 04, 2017 | By Dave Fornell
Over the past decade, several clinical studies have shown gadolinium-based magnetic resonance imaging (MRI) contrast...
Overlay Init